Sunmax Biotechnology Co Ltd (4728) - Net Assets
Based on the latest financial reports, Sunmax Biotechnology Co Ltd (4728) has net assets worth NT$1.44 Billion TWD (≈ $45.51 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.90 Billion ≈ $59.82 Million USD) and total liabilities (NT$454.35 Million ≈ $14.31 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 4728 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.44 Billion |
| % of Total Assets | 76.07% |
| Annual Growth Rate | 11.71% |
| 5-Year Change | 70.2% |
| 10-Year Change | N/A |
| Growth Volatility | 10.73 |
Sunmax Biotechnology Co Ltd - Net Assets Trend (2015–2024)
This chart illustrates how Sunmax Biotechnology Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Sunmax Biotechnology Co Ltd (4728) market capitalisation.
Annual Net Assets for Sunmax Biotechnology Co Ltd (2015–2024)
The table below shows the annual net assets of Sunmax Biotechnology Co Ltd from 2015 to 2024. Also explore Sunmax Biotechnology Co Ltd (4728) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.51 Billion ≈ $47.66 Million |
+6.09% |
| 2023-12-31 | NT$1.43 Billion ≈ $44.93 Million |
+7.60% |
| 2022-12-31 | NT$1.33 Billion ≈ $41.75 Million |
+29.48% |
| 2021-12-31 | NT$1.02 Billion ≈ $32.25 Million |
+15.16% |
| 2020-12-31 | NT$888.84 Million ≈ $28.00 Million |
+31.32% |
| 2019-12-31 | NT$676.83 Million ≈ $21.32 Million |
+4.45% |
| 2018-12-31 | NT$648.01 Million ≈ $20.42 Million |
+13.15% |
| 2017-12-31 | NT$572.70 Million ≈ $18.04 Million |
+3.14% |
| 2016-12-31 | NT$555.29 Million ≈ $17.49 Million |
-0.53% |
| 2015-12-31 | NT$558.24 Million ≈ $17.59 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sunmax Biotechnology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 79710300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$768.12 Million | 50.77% |
| Other Components | NT$744.72 Million | 49.23% |
| Total Equity | NT$1.51 Billion | 100.00% |
Sunmax Biotechnology Co Ltd Competitors by Market Cap
The table below lists competitors of Sunmax Biotechnology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nankang Rubber Tire Corp Ltd
TW:2101
|
$677.93 Million |
|
M31 Technology Corp
TWO:6643
|
$678.08 Million |
|
Dodla Dairy Limited
NSE:DODLA
|
$678.13 Million |
|
Shandong Mining Machinery Group Co Ltd
SHE:002526
|
$678.28 Million |
|
Jiahe Foods Industry Co. Ltd.
SHG:605300
|
$677.56 Million |
|
Kim Loong Resources Bhd
KLSE:5027
|
$677.56 Million |
|
Mavi Giyim Sanayi Ve Ticaret AS
IS:MAVI
|
$676.92 Million |
|
Qingdao Kutesmart Co Ltd
SHE:300840
|
$676.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sunmax Biotechnology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,426,046,000 to 1,512,838,000, a change of 86,792,000 (6.1%).
- Net income of 679,405,000 contributed positively to equity growth.
- Dividend payments of 599,093,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$679.40 Million | +44.91% |
| Dividends Paid | NT$599.09 Million | -39.6% |
| Other Changes | NT$6.48 Million | +0.43% |
| Total Change | NT$- | 6.09% |
Book Value vs Market Value Analysis
This analysis compares Sunmax Biotechnology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 14.22x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 37.25x to 14.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$10.60 | NT$395.00 | x |
| 2018-12-31 | NT$11.90 | NT$395.00 | x |
| 2019-12-31 | NT$12.43 | NT$395.00 | x |
| 2020-12-31 | NT$16.30 | NT$395.00 | x |
| 2021-12-31 | NT$18.77 | NT$395.00 | x |
| 2022-12-31 | NT$24.30 | NT$395.00 | x |
| 2023-12-31 | NT$26.15 | NT$395.00 | x |
| 2024-12-31 | NT$27.78 | NT$395.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sunmax Biotechnology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 44.91%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 71.58%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.22x
- Recent ROE (44.91%) is above the historical average (20.15%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -7.91% | -39.55% | 0.19x | 1.08x | NT$-99.99 Million |
| 2016 | 0.31% | 1.12% | 0.26x | 1.08x | NT$-53.79 Million |
| 2017 | 2.89% | 8.70% | 0.29x | 1.15x | NT$-40.74 Million |
| 2018 | 11.52% | 24.55% | 0.40x | 1.17x | NT$9.86 Million |
| 2019 | 14.84% | 16.91% | 0.53x | 1.64x | NT$32.76 Million |
| 2020 | 26.79% | 27.82% | 0.63x | 1.53x | NT$149.19 Million |
| 2021 | 24.00% | 23.72% | 0.70x | 1.45x | NT$143.28 Million |
| 2022 | 40.28% | 38.13% | 0.78x | 1.35x | NT$401.30 Million |
| 2023 | 43.88% | 37.05% | 0.78x | 1.51x | NT$483.10 Million |
| 2024 | 44.91% | 71.58% | 0.51x | 1.22x | NT$528.12 Million |
Industry Comparison
This section compares Sunmax Biotechnology Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,341,671,800
- Average return on equity (ROE) among peers: 5.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sunmax Biotechnology Co Ltd (4728) | NT$1.44 Billion | -7.91% | 0.31x | $677.77 Million |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $95.41 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $942.90 Million | 7.52% | 1.19x | $192.35 Million |
| Panion & BF Biotech Inc (1760) | $1.35 Billion | 11.79% | 0.36x | $145.06 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.77 Billion | 3.40% | 0.54x | $81.67 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $2.56 Billion | 15.36% | 0.11x | $104.38 Million |
| Level Biotechnology (3118) | $549.47 Million | 11.45% | 0.50x | $31.54 Million |
| GenMont Biotech Inc (3164) | $1.37 Billion | 3.33% | 0.09x | $44.17 Million |
| Medigen Biotechnology (3176) | $807.90 Million | 0.00% | 0.08x | $165.68 Million |
| Sagittarius Life Science (3205) | $674.50 Million | -17.72% | 0.20x | $99.91 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.47 Billion | 2.00% | 0.09x | $115.03 Million |
About Sunmax Biotechnology Co Ltd
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.